Guangzhou Fermion Technology Co. Ltd. has announced IND clearance by China’s National Medical Products Administration (NMPA) for FZ-008-145 to treat pain.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Researchers at Myrobalan Therapeutics Inc. and Myrobalan Therapeutics Nanjing Co. Ltd. have divulged macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, neurodegeneration, obesity, metabolic diseases, and inflammatory disorders.
Trawsfynydd Therapeutics Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Valo Health Inc. has disclosed tricyclic phthalazinone compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Ariceum Therapeutics GmbH has submitted an application with the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to conduct a phase I trial of [123I]-ATT-001, its iodine-123-labeled PARP inhibitor in patients with recurrent glioblastoma.
Prune belly syndrome (PBS), also known as Eagle-Barrett syndrome, is a rare multisystemic congenital myopathy that mainly affects males, and which is incompletely understood genetically speaking.
RSS
